CN111533749A - 一类苯并唑类-炔基-Tr*ger’s Base衍生物及其合成方法与应用 - Google Patents
一类苯并唑类-炔基-Tr*ger’s Base衍生物及其合成方法与应用 Download PDFInfo
- Publication number
- CN111533749A CN111533749A CN202010432499.9A CN202010432499A CN111533749A CN 111533749 A CN111533749 A CN 111533749A CN 202010432499 A CN202010432499 A CN 202010432499A CN 111533749 A CN111533749 A CN 111533749A
- Authority
- CN
- China
- Prior art keywords
- benzoxazole
- alkynyl
- base
- drying
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N21/643—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" non-biological material
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
- C09K2211/1033—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with oxygen
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
- C09K2211/1037—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with sulfur
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
技术领域
背景技术
金属离子在生命科学、环境科学等领域均具有极其重要的作用,因此其高灵敏度识别就显得尤为重要。高效离子识别的关键是识别分子的合理设计和合成。
苯并唑类化合物具有特殊的稠环共轭结构和良好的分子内电荷转移能力,使其具有许多优良的性能,在发光材料、OLED、抗菌抗肿瘤等诸多科学领域均具有广泛的应用。苯并唑类化合物具有较强的吸电子能力,能增强检测离子和探针分子之间的相互作用,选择性好,灵敏度高,热稳定性好,是一种结构比较稳定、性能比较优越的新型荧光材料和金属离子荧光探针。更为重要的是该类化合物易于进行结构修饰,可根据需求引入合适基团,调节整体分子结构,使其表现出不同的理化性质。
碳碳三键具有较好的电子传递能力。本发明基于苯并唑类的结构优势,结合TB独特的空间结构,在二者中间引入乙炔基,合成得到了一系列新型苯并唑-炔基-TB类化合物。
发明内容
本发明的目的在于,以对碘苯胺、多聚甲醛、4-乙炔基苯甲醛、1,4-二氧六环或二乙酮衍生物等原料通过缩合反应制得了一类具有聚集诱导发光、具有抗真菌活性、可用于金属离子识别的苯并唑类-炔基-Base衍生物。
S1:制备下式所示中间体2,
S2:制备下式所示中间体4
将中间体4、取代邻苯二胺和1,4-二氧六环置于干燥的茄型瓶中,回流一段,反应结束后冷却至室温,旋干溶剂,粗产物柱层析分离纯化,得目标产物11;
取代邻苯二胺的结构式如下式5所示,
其中,X为O、S或NH,R为H、4-CH3、4-Cl、4,5-CH3或4,5-Cl。
将中间体4、苯偶酰衍生物或9,10-菲醌和醋酸铵置于干燥的茄型瓶中,回流反应一段时间,反应结束后冷却至室温,旋干溶剂,粗产物柱层析分离纯化,得目标产物12;
其中,苯偶酰衍生物或9,10-菲醌的结构式如下式6-10所示,
进一步的,所述步骤S1具体包括:
将对碘苯胺和多聚甲醛混合,在低温下缓慢滴入三氟乙酸,滴完后在于低温下继续反应一段时间,之后缓慢升至室温,TLC跟踪反应结束;将反应混合物倒入冰水中,调节pH到中性,用二氯甲烷萃取,有机相再用饱和食盐水萃取,合并有机层,干燥,过滤,滤液减压蒸馏,柱层析分离纯化,再用丙酮重结晶,干燥后得中间体2。
进一步的,所述步骤S2具体包括
与现有技术相比,本发明的有益效果:
本发明以对碘苯胺、多聚甲醛、4-乙炔基苯甲醛、1,4-二氧六环或乙二酮衍生物等原料通过缩合反应制得一类可用于金属离子识别的具有聚集诱导发光的苯并唑类-炔基-Base衍生物,合成工艺所需反应条件温和、反应时间短、产率高,具有很好的规模化应用前景;
附图说明
图1为本发明实施例3中不同浓度Fe3+对11g相对荧光强度(RFI)的影响(左)(左)和研究配位比的job曲线(右)。
具体实施方式:
下面将结合附图和具体实施例,对本发明的技术方案进行清楚、完整地描述。显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
X=O or S or NH,R=H or 4-CH3 or 4-Cl or 4,5-CH3 or 4,5-Cl
具体包括:
(1)中间体2的制备
250mL干燥的圆底烧瓶中加入对碘苯胺(60mmol)和多聚甲醛(150mmol),冷却至-15℃,通过恒压滴液漏斗缓慢滴加120mL三氟乙酸,滴完后将反应体系移至室温反应7天,用冰水淬灭,氨水调pH到中性,二氯甲烷萃取(50mL×3),有机相再用饱和食盐水萃取(60mL×3),无水硫酸钠干燥,柱层析分离纯化(V石油醚:V乙酸乙酯=5:1),最后用丙酮重结晶,干燥,得中间体2。
(2)中间体4的制备
100mL双口瓶中加入2,8-二碘-TB(3mmol),4-乙炔基苯甲醛(6.3mmol),10%mmol四三苯基膦钯,10mL(2M)的碳酸钾溶液和30mL四氢呋喃,避光回流12h,反应结束后冷却至室温,二氯甲烷萃取(40mL×3),旋干溶剂,粗产物经柱层析分离(V石油醚:V乙酸乙酯=2:1)得中间体4。
(3)化合物11的制备
50mL干燥的茄型瓶中加入中间体4(0.1mmol)、取代邻苯二胺(0.24mmol)和25mL1,4-二氧六环,回流8h,反应结束后冷却至室温,旋干溶剂,粗产物经柱层析分离得到产物11。
(4)化合物12的制备
50mL干燥的茄型瓶中加入中间体4(0.1mmol)、苯偶酰衍生物或9,10-菲醌(0.1mmol)和25mL醋酸铵,回流2h,反应结束后恢复至室温,减压蒸掉多余溶剂,粗产物柱层析分离纯化,得目标产物12。
以化合物11a、12a为例详细说明其合成方法(化合物11b-11i的合成方法同11a,化合物12b-11e的合成方法同12a):
将化合物4(0.1mmol)、邻苯二胺(0.24mmol)和25mL1,4-二氧六环加到50mL干燥的茄型瓶中,回流8h,反应结束后冷却至室温,旋干溶剂,粗产物柱层析分离(V石油醚:V乙酸乙酯=1:2),得到产物11a,收率为60%。
化合物11a的结构式为:
分子式为:C45H30N6
中文命名为:
2,8-双((4-1H-苯并[d]咪唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(1H-benzo[d]imidazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methanodib enzo[b,f][1,5]diazocine
外观:砖红色固体
熔点:156.9-157.6℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ13.06(s,2H,N-H),8.19(s,3H,Ar-H),7.60(d,J=11.3Hz,10H,Ar-H),7.34-7.47(m,2H,Ar-H),7.31-6.88(m,7H,Ar-H),4.67(d,J=16.2Hz,2H,CH2-bridge),4.41-4.02(m,4H,2×CH2).
核磁共振碳谱:13C NMR(100MHz,DMSO-d6)δ150.95,149.41,133.77,132.75,132.59,132.56,132.30,132.07,131.97,130.40,129.44,129.35,129.24,127.27,127.14,126.92,124.17,122.26,117.34,100.00.
质谱:HRMS(ESI)m/z:calcd for C45H30N6:(M-H)+653.2454;found:653.2453.
50mL干燥的茄型瓶中加入中间体4(0.1mmol)、9,10-菲醌(0.1mmol)和25mL醋酸铵,回流2h,反应结束后冷却至室温,旋干溶剂,粗产物经柱层析(V石油醚:V乙酸乙酯=1:2)分离纯化,得目标产物12a。
化合物12a的结构式为:
分子式为:C61H42N6
中文命名为:
2,8-双((4-(4,5-二苯基-1H-咪唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(4,5-diphenyl-1H-imidazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methan odibenzo[b,f][1,5]diazocine
外观:金黄色固体
熔点:178.4-179.9℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ12.82(s,2H,N-H),8.11(d,J=8.0Hz,3H,Ar-H),7.69(s,1H,Ar-H),7.59(d,J=7.7Hz,4H,Ar-H),7.57-7.47(m,7H,Ar-H),7.45(s,4H,Ar-H),7.37(s,5H,Ar-H),7.31(s,4H,Ar-H),7.27-7.06(m,6H,Ar-H),4.68(d,J=16.7Hz,2H,CH2-bridge),4.36-4.11(m,4H,4H,2×CH2).
质谱:HRMS(ESI)m/z:calcd for C61H42N6:(M+H)+859.3549;found:859.3549.
其余产物结构表征:
化合物11b的结构式为:
分子式为:C49H38N6
中文命名为:
2,8-双((4-(5,6-二甲基-1H-苯并[d]咪唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine
外观:金黄色固体
熔点:>300℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ8.35(s,1H,Ar-H),8.17(d,J=7.0Hz,4H,Ar-H),7.87(s,5H,Ar-H),7.67(d,J=7.7Hz,3H,Ar-H),7.37(d,J=8.0Hz,2H,Ar-H),7.28-7.09(m,3H,Ar-H),4.67(d,J=16.3Hz,2H,CH2-bridge),4.38-4.12(m,4H,2×CH2),2.51(s,12H,4×CH3).
核磁共振碳谱:13C NMR(100MHz,DMSO-d6)δ150.00,149.38,133.77,132.75,132.59,132.56,132.23,132.07,131.97,131.95,130.78,130.74,130.61,129.35,129.24,126.89,123.77,117.37,100.00,91.57,88.79,20.57.
质谱:HRMS(ESI)m/z:calcd for C49H38N6:(M+H)+711.3236;found:71.3308.
化合物11c的结构式为:
分子式为:C45H26Cl4N6
中文命名为:
2,8-双((4-(5,6-二氯-1H-苯并[d]咪唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine
外观:深黄色固体
熔点:202.6-204.3℃.
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ13.39(s,2H,N-H),8.19(d,J=7.2Hz,3H,Ar-H),7.96(s,2H,Ar-H),7.78(s,3H,Ar-H),7.68(d,J=7.1Hz,3H,Ar-H),7.38(d,J=9.2Hz,3H,Ar-H),7.23(d,J=14.3Hz,4H,Ar-H),4.68(d,J=17.6Hz,2H,CH2-bridge),4.38-4.16(m,4H,2×CH2).
核磁共振碳谱:13C NMR(100MHz,DMSO-d6)δ160.67,153.55,153.54,149.48,145.26,132.38,132.36,130.84,130.79,129.47,129.26,127.55,127.47,127.43,124.90,117.23,116.39,100.00,92.09,88.59.
质谱:HRMS(ESI)m/z:calcd for C45H26Cl4N6:(M+H)+791.1051;found:791.1080.
化合物11d的结构式为:
分子式为:C47H34N6
中文命名为:
2,8-双((4-(5-甲基-1H-苯并[d]咪唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(5-methyl-1H-benzo[d]imidazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine
外观:金黄色固体
熔点:213.5-214.4℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ12.86(s,2H,N-H),8.15(t,J=12.5Hz,3H,Ar-H),7.65(d,J=6.4Hz,4H,Ar-H),7.55(s,2H,Ar-H),7.49-7.28(m,5H,Ar-H),7.26-7.13(m,3H,Ar-H),7.04(s,3H,Ar-H),4.68(d,J=16.7Hz,2H,CH2-bridge),4.36-4.05(m,4H,2×CH2),2.43(s,6H,2×CH3).
质谱:HRMS(ESI)m/z:calcd for C47H34N6:(M-H)+681.2767;found:681.2771.
化合物11e的结构式为:
分子式为:C45H28N4S2
中文命名为:
2,8-双((4-(苯并[d]噻唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(benzo[d]thiazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine
外观:深黄色固体
熔点:281.3-283.4℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ8.85(s,2H,Ar-H),8.71(s,2H,Ar-H),8.04(d,J=7.4Hz,3H,Ar-H),7.60(d,J=7.2Hz,4H,Ar-H),7.37(d,J=8.2Hz,2H,Ar-H),7.28-7.14(m,3H,Ar-H),7.05(s,2H,Ar-H),6.90(d,J=7.6Hz,2H,Ar-H),6.78(d,J=7.7Hz,2H,Ar-H),4.67(d,J=16.6Hz,2H,CH2-bridge),4.36-4.12(m,4H,2×CH2).
质谱:HRMS(ESI)m/z:calcd for C45H28N4S2:(M+H)+689.1834;found:689.1836.
化合物11f的结构式为:
分子式为:C45H28Cl2N6
中文命名为:
2,8-双((4-(5-氯-1H-苯并[d]咪唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine
外观:金黄色固体
熔点:189.6-191.3℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ8.20(d,J=8.1Hz,3H,Ar-H),7.68(d,J=8.3Hz,5H,Ar-H),7.63(d,J=8.2Hz,3H,Ar-H),7.39(d,J=8.7Hz,3H,Ar-H),7.30-7.12(m,6H,Ar-H),4.68(d,J=16.7Hz,2H,CH2-bridge),4.44-4.11(m,4H,2×CH2).13C NMR(100MHz,DMSO-d6)δ152.36,149.46,132.34,130.82,130.78,129.86,129.26,127.67,127.31,124.57,117.28,117.08,91.92,88.65.
质谱:HRMS(ESI)m/z:calcd for C45H28Cl2N6:(M-H)+726.1674;found:726.1672.
化合物11g的结构式为:
分子式为:C45H28N4O2
中文命名为:
2,8-双((4-(苯并[d]恶唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(benzo[d]oxazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine
外观:金黄色固体
熔点:227.3-228.2℃
核磁共振氢谱:1H NMR(400MHz,CDCl3)δ8.68(s,2H,Ar-H),7.88(d,J=7.5Hz,4H,Ar-H),7.58(d,J=7.3Hz,4H,Ar-H),7.37(d,J=7.7Hz,2H,Ar-H),7.31(d,J=7.9Hz,2H,Ar-H),7.15(d,J=8.0Hz,4H,Ar-H),7.02(d,J=8.2Hz,2H,Ar-H),6.91(t,J=7.5Hz,2H,Ar-H),4.73(d,J=16.5Hz,2H,CH2-bridge),4.36(s,2H,CH2),4.22(d,J=16.8Hz,2H,CH2).
核磁共振碳谱:13C NMR(100MHz,DMSO-d6)δ158.71,151.93,149.47,138.10,136.70,131.96,130.87,130.78,129.59,129.25,128.23,125.74,125.49,120.01,119.99,119.59,117.28,116.63,92.17,88.94.
质谱:HRMS(ESI)m/z:calcd for C45H28N4O2:(M+H)+657.2291;found:657.2298.
化合物11h的结构式为:
分子式为:C47H32N4O2
中文命名为:
2,8-双((4-(5-甲基苯并[d]恶唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(5-methylbenzo[d]oxazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methano dibenzo[b,f][1,5]diazocine
外观:深黄色固体
熔点:183.5-184.1℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ8.81(s,1H,Ar-H),8.72(s,1H,Ar-H),8.67(s,1H,Ar-H),8.05(d,J=8.0Hz,3H,Ar-H),7.61(d,J=7.8Hz,3H,Ar-H),7.37(d,J=8.0Hz,2H,Ar-H),7.28–7.15(m,3H,Ar-H),7.06(s,1H,Ar-H),6.90(d,J=7.7Hz,1H,Ar-H),6.78(d,J=8.0Hz,1H,Ar-H),6.50(d,J=7.7Hz,1H,Ar-H),6.39(s,1H,Ar-H),6.18(d,J=7.0Hz,1H,Ar-H),4.67(d,J=17.0Hz,2H,CH2-bridge),4.29(m,4H,2×CH2),2.25–2.06(m,6H,2×CH3).
质谱:HRMS(ESI)m/z:calcd for C47H32N4O2:(M-H)+683.2447;found:683.2460.
化合物11i的结构式为:
分子式为:C45H26ClN4O2
中文命名为:
2,8-双((4-(5-氯苯并[d]恶唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(5-chlorobenzo[d]oxazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methano dibenzo[b,f][1,5]diazocine
外观:深黄色固体
熔点:259.1-261.2℃
核磁共振氢谱:1H NMR(400MHz,CDCl3)δ8.64(s,2H,Ar-H),7.89(d,J=7.3Hz,3H,Ar-H),7.60(d,J=7.3Hz,3H,Ar-H),7.40(d,J=7.5Hz,2H,Ar-H),7.30(s,1H,Ar-H),7.14(d,J=10.9Hz,7H,Ar-H),6.96(d,J=8.0Hz,2H,Ar-H),4.73(d,J=17.4Hz,2H,CH2-bridge),4.37(s,2H,CH2),4.23(d,J=16.4Hz,2H,CH2).
核磁共振碳谱:13C NMR(100MHz,DMSO-d6)δ160.43,150.88,149.50,139.41,136.37,132.36,131.98,130.88,130.79,130.22,129.80,129.26,127.43,125.83,125.75,123.45,119.40,118.00,117.22,100.00,92.35,88.90.
质谱:HRMS(ESI)m/z:calcd for C45H26ClN4O2:(M+H)+725.1511;found:725.1494.
化合物12b的结构式为:
分子式为:C61H42N6
中文命名为:
2,8-双((4-(4,5-二苯基-1H-咪唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(4,5-diphenyl-1H-imidazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-methan odibenzo[b,f][1,5]diazocine
外观:金黄色固体
熔点:189.6-191.3℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ8.20(d,J=8.1Hz,3H,Ar-H),7.68(d,J=8.3Hz,5H,Ar-H),7.63(d,J=8.2Hz,3H,Ar-H),7.39(d,J=8.7Hz,3H,Ar-H),7.30-7.12(m,6H,Ar-H),4.68(d,J=16.7Hz,2H,CH2-bridge),4.44-4.11(m,4H,2×CH2).
核磁共振碳谱:13C NMR(100MHz,DMSO-d6)δ152.36,149.46,132.34,130.82,130.78,129.86,129.26,127.67,127.31,124.57,117.28,117.08,91.92,88.65.
质谱:HRMS(ESI)m/z:calcd for C45H28Cl2N6:(M-H)+726.1674;found:726.1672.
化合物12c的结构式为:
分子式为:C65H50N6
中文命名为:
2,8-双((4-(4,5-二对甲苯基-1H-咪唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(4,5-di-p-tolyl-1H-imidazol-2-yl)phenyl)ethynyl)-6H,12H-5,11-metha nodibenzo[b,f][1,5]diazocine
外观:橙色固体
熔点:189.2-190.9℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ8.13(s,1H,Ar-H),7.97(s,3H,Ar-H),7.83-7.50(m,16H,Ar-H),7.43(s,3H,Ar-H),7.31(s,2H,Ar-H),7.25(s,3H,Ar-H),6.99(s,2H,Ar-H),4.73(d,J=16.6Hz,2H,CH2-bridge),4.43-4.12(m,4H,2×CH2),2.56(s,12H,4×CH3).
质谱:HRMS(ESI)m/z:calcd for C65H50N6:(M+H)+915.4174;found:915.4169.
化合物12d的结构式为:
分子式为:C65H48Cl2N6O4
中文命名为:
2,8-双((4-(4-(2-氯苯基)-5-(3,4-二甲氧基苯基)-1H-咪唑-2-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2,8-bis((4-(4-(2-chlorophenyl)-5-(3,4-dimethoxyphenyl)-1H-imidazol-2-yl)phen yl)ethynyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine
外观:亮橙色固体
熔点:215.5-217.4℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ12.92(s,1H,N-H),12.71(s,1H,N-H),8.08(s,3H,Ar-H),7.92(s,2H,Ar-H),7.67(s,2H,Ar-H),7.64-7.45(m,6H,Ar-H),7.39(d,J=17.7Hz,4H,Ar-H),7.21(d,J=12.6Hz,3H,Ar-H),7.07(s,2H,Ar-H),6.88(m,4H,Ar-H),4.66(s,2H,CH2-bridge),4.44-4.01(m,4H,2×CH2),3.26(s,12H,4×OCH3).
质谱:HRMS(ESI)m/z:calcd for C65H48Cl2N6O4:(M+H)+1047.3192;found:1047.3195.
化合物12e的结构式为:
分子式为:C57H34ClN6
中文命名为:
2-((4-(7H-乙酰萘[1,2-d]咪唑-8-基)苯基)乙炔基)-8-((4-(6a,7-二氢-3H-乙酰萘[1,2-d]咪唑-8-基)苯基)乙炔基)-6H,12H-5,11-桥亚甲基二苯并[b,f][1,5]二氮芳辛
英文命名为:
2-((4-(7H-acenaphtho[1,2-d]imidazol-8-yl)phenyl)ethynyl)-8-((4-(6a,7-dihydro-3H-acenaphtho[1,2-d]imidazol-8-yl)phenyl)ethynyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine
外观:红棕色固体
熔点:168.5-169.4℃
核磁共振氢谱:1H NMR(400MHz,DMSO-d6)δ12.92(s,2H,N-H),8.26–8.08(m,4H,Ar-H),7.86(m,2H,Ar-H),7.71-7.59(m,4H,Ar-H),7.48(m,4H,Ar-H),7.37(d,J=8.1Hz,4H,Ar-H),7.26-7.11(m,3H,Ar-H),7.05(s,3H,Ar-H),4.72-4.61(m,2H,CH2-bridge),4.33-4.14(m,4H,2×CH2).
核磁共振碳谱:13C NMR(100MHz,DMSO-d6)δ192.98,188.12,149.77,144.83,135.85,132.83,132.82,132.81,132.79,132.78,132.35,131.06,130.92,130.21,129.45,129.43,129.30,129.01,128.90,125.77,121.78,121.73,116.84,93.66,88.33.
质谱:HRMS(ESI)m/z:calcd for C57H34ClN6:(M+H)+805.3080;found:805.3048.
化合物的物理性质(产率、熔点)如表1所示:
表1化合物的产率、熔点
实施例3金属离子检测
各化合物的金属离子识别实验结果如表2所示(除表2所示化合物外,其他化合物未发现对下列金属离子具有响应能力):
表2产物与7种金属离子作用后RFI的变化
“-”号表示加入金属离子后RFI的降低值,没有符号表示加入金属离子后RFI的增加值。
从表2可以看出,该类化合物对Fe3+、Al3+均有良好响应,RFI都有不同程度的变化。其中,化合物11g加入金属离子后荧光强度发生最明显、也最具有特异性的。
图1为不同浓度Fe3+对11gRFI的影响(左)和研究配位比的job曲线(右),从图中可以看出11g与Fe3+以1:2的方式进行配位。
实施例4抗真菌活性测试
采用MTT方法测定了产物对真菌标准株烟曲霉(AF1160)的抑制活性(表3),筛选到2个化合物有较好的抑菌效果,尤其是化合物11i,其抑菌浓度为10μg/mL。从结构上来看,将TB与咪唑或噁唑类化合物以三键连接在一起能够增强产物的抑菌效果。
表3化合物12和13对AF1160最低抑菌浓度(MIC,μg/mL)
Claims (6)
S1:制备下式所示中间体2,
S2:制备下式所示中间体4
将中间体4、取代邻苯二胺和1,4-二氧六环置于干燥的茄型瓶中,回流一段,反应结束后冷却至室温,旋干溶剂,粗产物柱层析分离纯化,得目标产物11;
取代邻苯二胺的结构式如下式5所示,
其中,X为O、S或NH,R为H、4-CH3、4-Cl、4,5-CH3或4,5-Cl。
将中间体4、苯偶酰衍生物或9,10-菲醌和醋酸铵置于干燥的茄型瓶中,回流反应一段时间,反应结束后冷却至室温,旋干溶剂,粗产物柱层析分离纯化,得目标产物12;
其中,苯偶酰衍生物或9,10-菲醌的结构式如下式6-10所示,
3.根据权利要求2所述的制备方法,其特征在于,所述步骤S1具体包括:
将对碘苯胺和多聚甲醛混合,在低温下缓慢滴入三氟乙酸,滴完后在于低温下继续反应一段时间,之后缓慢升至室温,TLC跟踪反应结束;将反应混合物倒入冰水中,调节pH到中性,用二氯甲烷萃取,有机相再用饱和食盐水萃取,合并有机层,干燥,过滤,滤液减压蒸馏,柱层析分离纯化,再用丙酮重结晶,干燥后得中间体2。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010432499.9A CN111533749B (zh) | 2020-05-20 | 2020-05-20 | 一类苯并唑类-炔基-Tröger’s Base衍生物及其合成方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010432499.9A CN111533749B (zh) | 2020-05-20 | 2020-05-20 | 一类苯并唑类-炔基-Tröger’s Base衍生物及其合成方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111533749A true CN111533749A (zh) | 2020-08-14 |
CN111533749B CN111533749B (zh) | 2022-07-19 |
Family
ID=71972501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010432499.9A Active CN111533749B (zh) | 2020-05-20 | 2020-05-20 | 一类苯并唑类-炔基-Tröger’s Base衍生物及其合成方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111533749B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113416196A (zh) * | 2021-07-07 | 2021-09-21 | 江苏师范大学 | 一种苯并噻二唑-tb类化合物及其合成方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104892616A (zh) * | 2015-05-25 | 2015-09-09 | 江苏师范大学 | 具有抗人肝癌HepG2细胞活性的TB类衍生物合成方法 |
CN108864111A (zh) * | 2018-07-24 | 2018-11-23 | 江苏师范大学 | 一种含苯并咪唑的Tr*ger’s base类化合物及其制备方法与应用 |
CN110627798A (zh) * | 2019-10-24 | 2019-12-31 | 江苏师范大学 | 一类Tr*ger’s base-Schiff碱衍生物及其制备方法与应用 |
-
2020
- 2020-05-20 CN CN202010432499.9A patent/CN111533749B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104892616A (zh) * | 2015-05-25 | 2015-09-09 | 江苏师范大学 | 具有抗人肝癌HepG2细胞活性的TB类衍生物合成方法 |
CN108864111A (zh) * | 2018-07-24 | 2018-11-23 | 江苏师范大学 | 一种含苯并咪唑的Tr*ger’s base类化合物及其制备方法与应用 |
CN110627798A (zh) * | 2019-10-24 | 2019-12-31 | 江苏师范大学 | 一类Tr*ger’s base-Schiff碱衍生物及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
ANANYA PAUL等: "Stabilization and Structural Alteration of the G‑Quadruplex DNA Made from the Human Telomeric Repeat Mediated by Tröger’s Base Based Novel Benzimidazole Derivatives", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
XIAOCHEN XU等: "Ionic polyimide membranes containing Troger’s base: Synthesis,microstructure and potential application in CO2 separation", 《JOURNAL OFMEMBRANESCIENCE》 * |
褚衍环: "新型Troger’s Base衍生物的合成及其荧光性衍生物的合成及其荧光性衍能研究", 《中国矿业大学硕士学位论文》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113416196A (zh) * | 2021-07-07 | 2021-09-21 | 江苏师范大学 | 一种苯并噻二唑-tb类化合物及其合成方法和应用 |
CN113416196B (zh) * | 2021-07-07 | 2022-05-10 | 江苏师范大学 | 一种苯并噻二唑-tb类化合物及其合成方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111533749B (zh) | 2022-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113121367B (zh) | 一种有机电致发光化合物及其制备方法与应用 | |
CN110615802B (zh) | 一类苯并咪唑并喹唑啉衍生物及其制备方法与应用 | |
CN110818743B (zh) | 一种具有聚集诱导发光性质的环金属铂配合物的制法及应用 | |
CN104326980A (zh) | 基于4,4’-联双芴结构的9,9’-位连接的主体材料及其应用 | |
CN111533749B (zh) | 一类苯并唑类-炔基-Tröger’s Base衍生物及其合成方法与应用 | |
CN107312013A (zh) | 一种通式化合物及有机电致发光的应用 | |
CN111499645B (zh) | 一类新型Tröger’s Base-咪唑衍生物及其制备方法与应用 | |
CN109535188A (zh) | 稠杂环化合物及其用途和有机电致发光器件 | |
CN112358472B (zh) | 一种有机化合物、电致发光材料及电致发光器件 | |
CN110627798B (zh) | 一类Tröger’s base-Schiff碱衍生物及其制备方法与应用 | |
CN107384374B (zh) | 一种聚集诱导发光及机械致增强发光材料及制备方法 | |
CN111620859B (zh) | 一种具有aie活性的材料 | |
CN110746423B (zh) | 芳基咪唑并菲啰啉荧光染料的合成及对金属离子的识别 | |
CN109134382B (zh) | 具有esipt与aie性质的菲并咪唑衍生物及其制备方法与应用 | |
CN114276334B (zh) | 一类咔唑烷基化芳杂环衍生物及其制备方法 | |
CN107915687B (zh) | 一种多取代吩嗪类衍生物及其氧化物的高效制备方法 | |
CN110105294A (zh) | 一种多取代四氢喹喔啉衍生物的制备方法 | |
CN113105459B (zh) | 一种三唑并嘧啶衍生物及其制备方法和应用 | |
CN105198889A (zh) | 一种6-芳基取代的咪唑并[4,5-c]吲哚并[2,3-a]咔唑衍生物及其制备方法 | |
CN111440178B (zh) | 苯并噻唑-Schiff碱-Tröger’s base衍生物及其制备方法与应用 | |
CN109384786A (zh) | 基于咪唑的同分异构体发光分子及其制备方法与应用 | |
CN110343109B (zh) | 一种二氢蝶啶酮-磺酰胺类衍生物及其药学上可接受的盐、其制备方法及其应用 | |
Xue et al. | Synthesis of diazadibenzo‐18‐crown‐6 ligands with appended chromophoric and fluorophoric groups as potential metal ion chemosensors | |
CN107820497A (zh) | 用于电子装置的咪唑吡嗪衍生物 | |
CN111533706A (zh) | 一种1,4,6-三取代1,2-二氢-三嗪类化合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |